恩特罗斯凝胶治疗儿童和青少年功能性腹痛的随机安慰剂对照研究方案
本研究为英国两中心、平行臂、随机双盲安慰剂对照试验,计划招募3-18岁诊断为功能性腹痛障碍的儿童和青少年,在2周观察期后按1:1随机接受恩特罗斯凝胶或匹配安慰剂每日两次共4周,随后全部开放标签治疗4周。主要结局为观察期与双盲期每日平均疼痛评分变化,次要结局包括胃肠道症状和生活质量。
要点
- 恩特罗斯凝胶是一种硅基肠道吸附剂,可吸附免疫蛋白、细菌分解产物和胆汁酸。
- 主要结局为双盲期与观察期相比每日平均疼痛评分的变化。
- 研究采用远程实施,干预措施通过邮寄发送。
核心结论
- 本研究将评估恩特罗斯凝胶治疗儿童和青少年功能性腹痛障碍的疗效、耐受性和安全性。
研究设计与样本
- 英国两中心、平行臂、随机、双盲、安慰剂对照试验。
- 计划招募3-18岁诊断为功能性腹痛障碍且已排除其他显著胃肠道疾病的儿童和青少年。
- 经过2周观察期后,按1:1随机接受恩特罗斯凝胶或匹配安慰剂每日两次,双盲治疗4周,随后全部开放标签接受恩特罗斯凝胶治疗4周。
关键数值与推荐
- 主要结局为观察期与双盲期相比,恩特罗斯凝胶组与安慰剂组每日平均疼痛评分的变化。
- 次要结局包括基线和6周、10周时胃肠道症状(PedsQL™ 3.0 GIS模块)和生活质量(KIDSCREEN-27)的变化。
- 儿童在父母/照顾者支持下使用Wong-Baker FACES疼痛评定量表每日记录腹痛。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Functional abdominal pain disorders (FAPDs) comprise of irritable bowel syndrome, functional dyspepsia, abdominal migraine and functional abdominal pain not otherwise specified. FAPDs are common in children worldwide, decrease health related quality of life, reduce attendance and participation in school and after-school activities similar to children with inflammatory bowel disease, and incur significant health care costs. The aetiology is thought to involve structural and/or functional disruptions in one or more elements of the microbiota-gut-brain axis. Several different treatment approaches are available, reflecting that none is proven to have significant efficacy. The medical device Enterosgel®, a silicon-based intestinal absorbent, adsorbs immune proteins, bacterial breakdown products and bile acids and normalises the intestinal microbiota. Enterosgel® is effective in irritable bowel syndrome with diarrhoea in adults and is available on prescription and over-the-counter. We plan to evaluate the efficacy, tolerability and safety of Enterosgel® in the treatment FAPDs in children and young people. METHODS: In a UK two-centre, parallel arm, randomised, double-blind, placebo-controlled trial, we will recruit children aged 3-18 years diagnosed with a FAPD during a routine health facility assessment and in whom other significant gastrointestinal disorders have been excluded. After an initial 2-week observation phase, eligible children will be randomised 1:1 to receive Enterosgel® or a matching placebo drink twice daily for 4 weeks during the double-blind treatment phase, then all children will receive open-label Enterosgel® treatment for a further 4 weeks. With support from parents/carers, children will record abdominal pain daily using the Wong-Baker FACES Pain Rating Scale. The primary outcome is change in mean daily pain score during the initial observation phase and the double-blind phase in the Enterosgel® versus the placebo arm. Secondary outcomes include change in gastrointestinal symptoms (assessed PedsQL™ 3.0 GIS module) and quality of life (KIDSCREEN-27) recorded at baseline and 6 and 10 weeks. After the initial clinical assessment, all procedures will be conducted remotely with study interventions sent by post. DISCUSSION: In the absence of a currently available effective treatment, this study will assess the acceptability, efficacy and safety of Enterosgel® in the treatment of children and young people with FAPDs. TRIAL REGISTRATION: ISRCTN ISRCTN16474818. Registered on 21 May 2025, https://www.isrctn.com/ISRCTN16474818.
引用
- Howell CA, Nair MV, Auth MK, et al. Randomised, placebo-controlled study to assess the safety and efficacy of Enterosgel® in the treatment of functional abdominal pain in children and young people (ENTOPIC): study protocol for a clinical trial. Trials. 2026. PMID: 42902396. doi:10.1186/s13063-026-09913-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。